Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. Tiered royalties on net sales are also included in the deal. FAP-2286 is being investigated as a peptide-targeted radionuclide therapy.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. The company stated that the collaboration will use the local presence, sales and marketing capabilities of Biomm in Brazil.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

pharmaphorum

FEBRUARY 11, 2022

If consummated, the deal would bring in around €350 million for Ipsen , leaving the company as a specialty pharma pure-play in cancer, rare diseases and neuroscience and ending its strategy of adopting a combined prescription and over-the-counter (OTC) medicines business model. billion takeover of Clementia Pharma in 2019.

Sales 103

Sales Pharma Companies Branding Cosmetics 103

Pharmacy Checkers

DECEMBER 5, 2019

A new Chinese law (in effect as of December 1, 2019) makes third-party online platform medicine sales legal, appropriately ends a draconian definition of counterfeit drugs, and effectively decriminalizes personal drug importation, but with a lot of gray! Decriminalizing Personal Drug Importation and Redefining “Counterfeit”.

Sales 64

Sales Medicine Pharmacy Drugs 64

Pharmaceutical Technology

DECEMBER 9, 2022

Pharmaceutical sales in Brazil reached $17bn in 2021, according to GlobalData figures. Brazilian public spending on healthcare, drug pricing reforms and remote medicine. of the total value of pharmaceutical market sales, with the value of generics sales forecast to grow to $5.7bn in 2022. Free Whitepaper.

Marketing 246

Marketing Sales Production Medicine 246

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Pharmaceutical Technology

NOVEMBER 4, 2022

For the quarter, total product sales were recorded at $6.2bn, a 1% drop from $6.3bn in Q3 2021. The drop in global product sales led to the decline in total revenue for the third quarter of this year, the company noted. This growth reflects the strong underlying demand for our medicines and the value they bring to patients.”.

Sales 130

Sales Production Licensing Licensing 130

Pharmaceutical Technology

JANUARY 4, 2023

Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. The company will also receive tiered royalties on sales of the product.

Licensing 130

Licensing Licensing Clinical Development Sales 130

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

FEBRUARY 3, 2023

Goldfinch Bio’s assignment estate will receive an upfront payment of $15m and is eligible for milestone payments of up to $520m for each licensed TRPC4/5 candidate, from which $410m relates to regulatory approval and commercial sales milestones. Additionally, the company will receive a royalty on net sales of each licensed product.

Licensing 130

Licensing Licensing Sales Development 130

Pharmaceutical Technology

MAY 8, 2023

Under the terms of the license and commercialisation deal, Dr. Reddy’s will get licence for the development and commercialisation of toripalimab in India, Panama, Peru, Colombia, South Africa, Brazil, Argentina, Chile, Uruguay, and Mexico. Junshi Biosciences may get an aggregate of up to $728.3m

Development 130

Development Marketing Licensing Licensing 130

pharmaphorum

FEBRUARY 3, 2022

Legislation is already in place allowing companies to grow the plant for medicinal purposes under license, doctors have been able to prescribe it since 2017 with full reimbursement from health insurers. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 119

Licensing Licensing Marketing Medicine 119

Pharmaceutical Technology

MARCH 31, 2023

Brexafemme is a novel, approved anti-fungal medicine with a broad spectrum of activity against existing and emerging resistant strains of fungi. in sales-related milestone payments, along with tiered royalties on sales across all indications. Additionally, GSK will pay up to $242.5m

Sales 130

Sales FDA Approval Clinical Trials Clinical Trials 130

Pharmaceutical Technology

OCTOBER 18, 2022

Gilead holds an option for licensing MGD024 as a possible therapy to treat specific blood cancers, including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.

Antibody 130

Antibody Development Sales Clinical Trials 130

XTalks

DECEMBER 18, 2024

Trial data for both the pediatric and adult trials were published in The New England Journal of Medicine. Neurocrines hit drug generated $613 million in sales during the third quarter and is projected to reach $2.3 Neurocrines hit drug generated $613 million in sales during the third quarter and is projected to reach $2.3

Genetics 116

Genetics Hormones Trials Drugs 116

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks.

Development 242

Development Bioequivalency Generic Drugs Production 242

Pharmaceutical Technology

MARCH 29, 2023

The partnership pursues an innovative approach to discovering and developing new medicines, using many of the modality-agnostic precision medicine platforms of Evotec. Together with our BMS colleagues, we are confident that we will deliver new medicines that matter to patients with neurodegenerative diseases.”

Clinical Trials 130

Clinical Trials Clinical Trials Insulin Medicine 130

Pharmaceutical Technology

AUGUST 4, 2022

The company could also receive a total of up to $6bn in research, development, launch and net sales milestones and other payments, in addition to tiered royalty payments on net product sales, across various programmes. This would help them co-develop further allogeneic CAR-T product candidates for current and new hematologic targets.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. .

Development 130

Development Gene Therapy Genetics Gene 130

Pharmaceutical Technology

FEBRUARY 22, 2023

Spanish pharmaceutical firm Ferrer and Swiss biotechnology firm Asceneuron have signed a licensing agreement for the latter’s O-GlcNAcase inhibitor, ASN90, to treat progressive supranuclear palsy (PSP). Additionally, Asceneuron is eligible for tiered double-digit royalties on ASN90’s global net sales.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JUNE 5, 2023

PharmaEssentia may be entitled to receive certain milestone payments along with royalties based on sales of the product. In 2019, the European Medicines Agency approved the therapy, which has also been licensed in Japan, Taiwan and South Korea. It holds orphan drug designation in the US to treat PV.

Marketing 130

Marketing Licensing Licensing Sales 130

Pharmaceutical Technology

SEPTEMBER 2, 2022

In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. This is where partners such as Abacus Medicine Pharma Services can really help,” says Simon Estcourt, managing director of Abacus Medicine Pharma Services.

Drugs 130

Drugs Pharma Companies Medicine Production 130

Pharmaceutical Technology

MAY 25, 2023

Adalvo has entered a strategic licensing agreement with Swiss pharmaceutical company EQL Pharma for Mellozzan (melatonin) outside Europe and the US. With a network of more than 134 local pharmaceutical companies, Adalvo supplies more than 110 different medicines in over 100 countries across the world.

Hormones 130

Hormones Engineer Containment Licensing 130

The Pharma Data

AUGUST 5, 2020

AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Redx is also eligible to receive up to $360m in additional payments, dependent on development, regulatory and commercial milestones, as well as tiered royalties on any future sales.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. ,

Licensing 52

Licensing Licensing Clinical Development Sales 52

Pharma in Brief

FEBRUARY 5, 2024

The Federal Court of Appeal ( FCA ) has held that the sale of single dose of a patented multi-dose regimen does not provide an implied license to use the entire patented dosing regimen. Janssen commenced an infringement action under section 6 of the Patented Medicines (Notice of Compliance) Regulations. Pharmascience Inc. (

Sales 52

Sales Medicine Production Compliance 52

Pharmaceutical Technology

NOVEMBER 27, 2022

Additionally, ADC Therapeutics will have an option for licensing chosen antibodies in the future for international development and marketing of antibody-drug conjugates (ADCs). . On net product sales, the company will also receive single-digit royalty payments.

Antibody 130

Antibody Licensing Licensing Development 130

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

Druggist

NOVEMBER 6, 2020

Patients commonly request over the counter medicines for a chesty cough. In today’s post, I will seek to find the best medicine for chesty cough by looking at over the counter and pharmacy-only products available in the UK. The best evidence for or against the effectiveness of medicines comes from well designed clinical trials.

Medicine 69

Medicine Containment Production Pharmacy 69

Drug Channels

APRIL 15, 2025

We also offer licenses to our secure hosted learning environmentno internal setup required! Sorry, individual licenses are not currently available.) You'll learn how money and medicines move between manufacturers, wholesalers, pharmacies, PBMs, and payersand how each relationship affects costs and outcomes.

Pharmacy 52

Pharmacy Licensing Licensing Drugs 52

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. The company will also receive tiered global net sales royalties.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

SEPTEMBER 28, 2022

Seagen also will make potential development, regulatory and commercial milestone payments of up to nearly $650m, as well as royalty payments on the sales of the product in the future. According to the deal, Lava will receive an upfront payment of $50m from Seagen for the exclusive worldwide licence of LAVA-1223.

Development 130

Development Licensing Licensing Production 130

The Pharma Data

NOVEMBER 9, 2021

Group sales rise by 14.3 percent to 2.089 billion euros / Crop Science reports strong increase in sales and earnings / Pharmaceuticals and Consumer Health again post considerable sales growth / Core earnings per share advance by 29.6 percent (Fx & portfolio adj.) percent to 1.05

Sales 52

Sales Licensing Licensing Production 52

pharmaphorum

NOVEMBER 24, 2020

The combined company will cover a broad swathe of the digital health landscape, bringing together population health software, telehealth services, digital pharmacy delivering compounded and manufactured medicines, and tech enabled behavioural health services for people with mental health and substance abuse issues.

Behavioural Health 138

Behavioural Health Pharmacy Packaging Packaging 138

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets. About Novartis.

Gene Therapy 52

Gene Therapy Licensing Licensing Gene 52

pharmaphorum

JULY 14, 2022

Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales of €117 million last year. Grünenthal will make the purchase in cash upfront, with the final figure dependent on any closing adjustments.

Drugs 97

Drugs Sales Pharma Companies Cardiology 97